2023-10-18 10:39:44来源：2023年欧洲肿瘤内科学会（ESMO）年会 医脉通编译阅读：14次
2023年欧洲肿瘤内科学会（ESMO）年会将于10月20日-24日在西班牙马德里召开。ESMO大会涵盖基础研究、转化研究以及最新临床研究进展，将为临床实践、多学科讨论等提供广阔、卓越的学术平台。医脉通特整理了妇科肿瘤领域重磅研究，以飨读者。
口头报告1-妇科肿瘤
Proffered Paper session 1 - Gynaecological cancers
日期：2023年10月20日，星期五
时间：16:00 - 17:30
主席：David SP Tan (Singapore, Singapore)，Ana Oaknin (Barcelona, Spain)
地点：Sevilla Auditorium - Hall 9
01
摘要号：LBA36
标题：Efficacy and Safety of Senaparib as Maintenance Treatment in Patients with Newly Diagnosed Advanced Ovarian Cancer (FLAMES Study): A Randomized, Double-blind, Placebo-controlled, Phase 3 Trial
报告人：吴小华（中国，上海）
时间：16:00 - 16:10
02
摘要号：LBA37
标题：Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: Primary analysis of the double-blind placebo (pbo)-controlled ENGOT-Ov41/GEICO 69-O/ANITA phase 3 trial
报告人：Antonio Gonzalez Martin (Madrid, Spain)
时间：16:10 - 16:20
03
摘要号：LBA38
标题：Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
报告人：Domenica Lorusso (Rome, Italy)
时间：16:45 - 16:55
04
摘要号：LBA39
标题：Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase 3 trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)
报告人：Ana Oaknin (Barcelona, Spain)
时间：16:55 - 17:05
口头报告2-妇科肿瘤
Proffered Paper session 2 - Gynaecological cancers
日期：2023年10月21日，星期六
时间：08:45 - 10:00
主席：Domenica Lorusso (Rome, Italy)，Sven Mahner (München, Germany)
地点：Bilbao Auditorium - NCC
01
摘要号：LBA40
标题：Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma.
报告人：Nicoletta Colombo (Milan, Italy)
时间：08:45 - 08:55
02
摘要号：LBA41
标题：Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): results from the Phase III DUO-E/GOG-3041/ENGOT-EN10 trial
报告人：Shannon N. Westin (Houston, United States of America)
时间：09:15 - 09:25
03
摘要号：LBA42
标题：Olaparib vs placebo as maintenance therapy after platinum-based chemotherapy in advanced/metastatic endometrial cancer patients: The GINECO randomized phase IIb UTOLA trial
报告人：Florence Joly Lobbedez (Caen, Cedex 5, France)
时间：09:25 - 09:35
迷你口头报告-妇科肿瘤
Mini Oral session - Gynaecological cancers
日期：2023年10月22日，星期日
时间：10:15 - 11:55
主席：Christian Marth (Innsbruck, Austria)，Alexandra Leary (Villejuif, France)，Kosei Hasegawa (Saitama, Japan)
地点：Valencia Auditorium - Hall 10
01
摘要号：LBA43
标题：Updated Response Data and Analysis of Progression Free Survival by Mechanism of Mismatch Repair Loss in Endometrial Cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial
报告人：Ramez N. Eskander (La Jolla, United States of America)
时间：10:15 - 10:20
02
摘要号：740MO
标题：Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
报告人：Mansoor Raza Mirza (Copenhagen, Denmark)
时间：10:20 - 10:25
03
摘要号：742MO
标题：Neoadjuvant immune checkpoint blockade in mismatch repair deficient endometrial cancer
报告人：Marco De Bruyn (Groningen, Netherlands)
时间：10:25 - 10:30
04
摘要号：741MO
标题：Luveltamab Tazevibulin (STRO-002), an anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate (ADC), Demonstrates Clinical Activity in Recurrent/Progressive Epithelial Endometrial Cancer (EEC): STRO-002-GM1 Phase 1 Dose Expansion
报告人：Bhavana Pothuri (New York, United States of America)
时间：10:30 - 10:35
05
摘要号：743MO
标题：Efficacy and safety of QL1706 plus paclitaxel and cisplatin/carboplatin +/- bevacizumab (Bev) as 1L treatment in recurrent or metastatic cervical cancer (r/mCC): a single-arm, multicenter phase II study
报告人：王丹波（中国，沈阳）
时间：10:50 - 10:55
06
摘要号：744MO
标题：AdvanTIG-202: Phase 2 Randomized, Multicenter, Open-Label Study of Tislelizumab (TIS) With or Without Ociperlimab (OCI) in Patients (pts) With Previously Treated Recurrent/Metastatic (R/M) Cervical Cancer (CC)
报告人：Jung-Yun Lee (Seoul, Korea, Republic of)
时间：10:55 - 11:00
07
摘要号：LBA44
标题：Camrelizumab plus famitinib versus camrelizumab alone and investigator’s choice of chemotherapy in women with recurrent or metastatic cervical cancer
报告人：吴小华（中国，上海）
时间：11:00 - 11:05
08
摘要号：LBA45
标题：Overall Survival (OS) Outcomes from NRG-GY004, a Phase III Study Comparing Single-Agent Olaparib or Combination Cediranib and Olaparib to Platinum (Plat) Based Chemotherapy in Recurrent Plat Sensitive Ovarian Cancer (OvCa)
报告人：Joyce F. Liu (Boston, United States of America)
时间：11:15 - 11:20
09
摘要号：746MO
标题：Randomized phase II trial of durvalumab in combination with olaparib and cediranib (DOC) compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of care chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY023)
报告人：Jung-Min Lee (Bethesda, United States of America)
时间：11:20 - 11:25
10
摘要号：745MO
标题：Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): subgroup analysis of a first-in-human phase 1 study
报告人：Kathleen N. Moore (Oklahoma City, United States of America)
时间：11:35 - 11:40
11
摘要号：747MO
标题：First results from the ENGOT-GYN2/GOG-3051/BOUQUET phase 2 biomarker-directed platform study: cobimetinib (cobi) or atezolizumab (atezo) + bevacizumab (bev) for persistent/recurrent rare epithelial ovarian cancer (eOC)
报告人：Isabelle L. Ray-Coquard (Lyon, France)
时间：11:40 - 11:45
备注：排名不分先后，按照摘要号进行
如有遗漏或任何问题，请给我们留言~